Literature DB >> 2801602

Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.

J Verweij1, P C de Jong, P H de Mulder, P van der Broek, J Alexieva-Figusch, W L van Putten, J H Schornagel, L A Ravasz, G B Snow, J B Vermorken.   

Abstract

Induction combination chemotherapy with cisplatin, 100 mg/m2 i.v. day 1, and 5-fluorouracil, 1,000 mg/m2/24-h infusion days 1-4, was applied in 76 patients with locally far advanced squamous-cell cancer of the head and neck. The treatment program consisted of 3 cycles of chemotherapy, followed by local radiotherapy and/or surgery. Hematologic side effects were leukocytopenia (50%) and thrombocytopenia (35%). Other side effects included renal toxicity (23%), nausea and/or vomiting (86%), alopecia (18%), and phlebitis (45%). Thirteen patients (17%) achieved a complete remission and 37 patients (49%) a partial remission. Median progression-free and overall survival were 8 and 11 months, respectively. Only patients achieving a complete remission had a better prognosis. Although induction chemotherapy may facilitate further local treatment in about half of the patients, on the basis of presently available data, this procedure should not be routinely applied with the aim of better survival.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801602     DOI: 10.1097/00000421-198910000-00012

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  The role of neoadjuvant and adjuvant chemotherapy regimens consisting of different combinations of drugs in the treatment of advanced oral cancer.

Authors:  S Basu; M Khanra; B Dash; J Majumdar; J Biswas; P Chaudhuri
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.

Authors:  T Nakano; H Ikegami; S Nakamura; T Kawase; H Nishikawa; S Yokota; M Yoshida; T Tachibana; T Igarashi; K Komuta; K Higashino
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.